Global Studies Across the US and China Will Generate Real-World Evidence to Advance, Expand, and Strengthen the Myopia Management Category
[SINGAPORE, 18 May 2026]—CooperVision today announced the complete enrollment of its global MiSight® 1 day post-approval clinical studies (PAS) in the United States and China, a milestone in real-world evidence generation for pediatric myopia control. Together with the 7-year clinical trial of ActivControl® Technology, these studies represent the longest clinical evidence program ever undertaken for contact lens-based myopia control intervention in children,* including both randomized controlled efficacy trials and large-scale safety registries.1
The combined PAS programs span more than 100 clinical sites and include over 3,000 children.1 Data will supplement already extensive MiSight® 1 day clinical studies, which have been widely published and cited in the ophthalmology and optometry communities.
The announcement coincides with 2026 Myopia Awareness Week (May 18 – 24), reinforcing the company’s ongoing commitment to advancing the science and understanding of pediatric myopia, a condition expected to affect nearly half of the global population by 2050.2
In the Asia Pacific region, CooperVision is also leading the first of its kind collaboration bringing together ophthalmology and optometry to align on the clinical use of contact lenses for myopia control. The joint position statement provides clear, consensus-based guidance on key aspects of care—including appropriate age range, fitting approach, treatment goals, and criteria for discontinuation—reflecting a shared commitment to improving standards of care for the growing number of children affected by myopia. To support uptake and understanding, CooperVision has developed a concise data visualization video highlighting the statement’s core recommendations, accompanied by expert commentary from two of the statement’s authors, reinforcing the importance of cross disciplinary collaboration in advancing paediatric myopia management.
“Completing enrollment is a crucial step, allowing us to start analyzing data that will further illustrate how MiSight® 1 day performs in real-world settings over multiple years,” said Kathryn Richdale, OD, PhD, Director of Post-Market Clinical Affairs, CooperVision. “The findings will further strengthen the existing evidence supporting MiSight® 1 day, helping eye care professionals continue to make informed myopia management decisions and reinforcing long-term confidence for families.”
Participants in the multi-year studies represent populations across the U.S. and China, providing insights applicable to children worldwide. Final data are expected on a rolling basis between 2027 and 2030.
Building on this latest milestone, CooperVision has also released Progress in Focus: The Global Impact of MiSight® 1 day. The report brings together the far-reaching body of evidence and highlights the evolution of the MiSight® family of products. The resource reflects CooperVision’s broader commitment to advancing myopia management through ongoing research and innovation, while supporting eye care professionals in their conversations with patients, parents, and colleagues.
To learn more about CooperVision’s myopia management research journey, visit https://coopervision.com.hk/myopia-management
# # #
About CooperVision
CooperVision, a division of CooperCompanies (Nasdaq: COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life’s beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women’s healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com.
Media Contact
Laura DiCaprio, APR
McDougall Communications for CooperVision
laura@mcdougallpr.com or +1-585-434-2148
References:
1. CVI data on file, 2026.
2. Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-1042.
©2026 CooperVision.
MiSight® are registered trademark of The Cooper Companies, Inc. and its subsidiaries.
SA18515